# A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia

> **NCT05598320** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ascendis Pharma Growth Disorders A/S** · enrollment: 84 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** TransCon CNP
- **DRUG:** Placebo for TransCon CNP

## Key facts

- **NCT ID:** NCT05598320
- **Lead sponsor:** Ascendis Pharma Growth Disorders A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-03
- **Primary completion:** 2024-08-09
- **Final completion:** 2025-08-13
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598320, "A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05598320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*